ATA Launches ATA Academy to Address Tinnitus Provider Education Gap
ATA Academy is an online education platform aimed at training audiologists and other healthcare providers in evidence-based tinnitus assessment and management.
Tag: Lenire
All
Latest
All
Latest
Tinnitus UK Rates Lenire as Most Effective Tinnitus Treatment Option
Tinnitus UK has named Lenire by Neuromod as the highest-rated tinnitus treatment for safety and effectiveness.
All
Latest
Neuromod’s Tinnitus Treatment Device Validated by Clinical Trial Results
Nature Communications published peer-reviewed results of Neuromod's TENT-A3 clinical trial, validating its tinnitus treatment device, Lenire.
Neuromod Publishes Clinical Trial for Lenire Device
An international team, including a University of Minnesota professor, has published a second large clinical trial for a novel neuromodulation device, Lenire, that could reduce symptoms for millions worldwide with tinnitus, commonly described as “ringing in the ears.” Researchers published the results of the Treatment Evaluation of Neuromodulation for Tinnitus – Stage A2 (TENT-A2) clinical trial in “Nature – Scientific Reports.” An article detailing the research appears on the University of Minnesota website.
Read More
Neuromod Publishes Results of TENT-A2 Study
results of the company’s TENT-A2 (Treatment Evaluation of Neuromodulation for Tinnitus – Stage A2) clinical trial in “Nature – Scientific Reports” in a paper titled “Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial.”
Read More
Usability of Bimodal Neuromodulation to Treat Tinnitus
It is reported that 10-15% of the global adult population suffers from tinnitus 1-4, the chronic phantom auditory percept that has been attributed to abnormal firing patterns in the brain.4 According to the American Tinnitus Association (ATA), 45 million Americans reported experiencing tinnitus in the US Centers for Disease Control (CDC) National Health and Nutritional Examination Survey.
Read More
Neuromod Establishes Global Leadership Team
Neuromod Devices Ltd has announced the formation of a global commercial leadership team to direct the commercialization of its Lenire tinnitus treatment device through key partnerships.
Read More
Neuromod Announces Lenire Tinnitus Study Results
Neuromod Devices Ltd announced the findings of an independent study performed at the German Hearing Center (DHZ) at Hannover Medical School, which found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms (based on the Tinnitus Handicap Inventory score[i] across 20 patients) when using the Lenire treatment device.
Read More
‘Wired’ Article Suggests Apps and Devices to Help with Tinnitus
Described as a “phantom sound generated by the brain” by audiologist Julie Prutsman, tinnitus is a common condition experienced as ringing or buzzing in the ears, often caused by loud noise exposure. While there is no “cure” for tinnitus, there are methods of coping, according to a recent article in “Wired.”
Read More
Neuromod Launches Ótologie Tinnitus Telehealth Service
Medical device company, Neuromod Devices Ltd, announced that it has launched Ótologie, a “specialist telehealth service for tinnitus.” This new service will provide tinnitus patients, throughout the United Kingdom and Europe, with a private care option to avoid waiting lists and give them immediate access to treatment from its telehealth service.
Read More
Neuromod USA Appoints Teri Minard As Director, Gov Sales
Neuromod Devices Ltd, the medical device company which specializes in neuromodulation technologies, has announced the appointment of Teri Minard as Director, Government Sales of its recently established US entity, Neuromod USA Inc.
Read More
Neuromod Appoints Eric Timm as US CEO
Neuromod Devices Ltd, the medical device company which specializes in neuromodulation technologies, has announced the appointment of Eric Timm as Chief Executive Officer of its recently established US entity, Neuromod USA Inc, effective from October 1, 2021.
Read More
Neuromod Appoints Diarmuid Flavin as COO
The Dublin-based tinnitus device maker has hired Diarmuid Flavin as its new COO, after announcing last week the establishment of its US headquarters in Oakbrook, Ill, and the appointment of several well-known hearing industry experts.
Read More
Neuromod Opens USA HQ
Neuromod Devices Ltd, the Irish medical device company specializing in the treatment of tinnitus, has announced the establishment of Neuromod USA Inc, headquartered in Oak Brook, Ill. Three executives with significant experience in the hearing health industry have been appointed to the Neuromod USA leadership team as the organization prepares to enter the US market with its medical device for tinnitus treatment, pending approval from the Food and Drug Administration (FDA).
Read More
Neuromod Appoints Susan Whichard to Board
Whichard has more than 30 years’ experience in the hearing industry, having worked as both a business executive and a practicing healthcare professional, as a clinical audiologist. Her appointment comes as Neuromod plans continued expansion of the availability of Lenire, its tinnitus treatment device across Europe and in the US, pending FDA approval, according to the company’s announcement.
Read More
Survey Shows Many Don’t Receive Tinnitus Treatment
New research from Irish medical device company, Neuromod Devices Ltd, has found that more than three quarters of people suffering from tinnitus in the United Kingdom have never received any treatment for their condition, according to an announcement on the company’s website. The poll also revealed that 67% of UK tinnitus sufferers don’t feel adequately informed about their condition.
Read More
Neuromod Raises $12.4 Million in Series B Funding for Lenire Tinnitus Treatment Device
The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.
Read More
Neuromod Publishes Results of Tinnitus Study Utilizing Non-invasive Stimulation Device
The clinical trial was conducted between 2016 and 2019 and was designed to track changes in tinnitus symptom severity. The trial investigated the bimodal neuromodulation approach, using Neuromod’s non-invasive stimulation device that delivers sound to the ears and electrical stimulation to the tongue.
Read More